Group items tagged

The Conquer Cancer Foundation was founded by cancer doctors at the American Society of Clinical Oncology to support dramatic advances in the prevention, treatment, and cures of all types of cancer. To that end, CCF is accepting applications for its Global Oncology Young Investigator Award. Through the program, a single grant of up to $50,000 will be awarded to an early-career investigator in support of global oncology research. "Global oncology" as defined by the foundation implies an approach to the practice of oncology that acknowledges the reality of limited resources in most parts of the world. Projects therefore need to be a research exercise - identifying training models, researching their outcomes, analyzing the outcomes of those models to select the most effective curriculum, and/or researching the cost of creating sustainable models where they do not exist.

The Neuroendocrine Tumor Research Foundation (NETRF) is the largest private funder of NET research. Since 2005, NETRF has funded $22 million in scientific research to expand the molecular understanding of NETs and help drive personalized treatment options for patients.  To that end, NETRF has issued a 2019 Request for Applications (RFA) for innovative research that increases our basic understanding of these uncommon tumors and leads to the development of more effective therapies. Grants ranging from $100,000 to $1.2 million will support projects over one to four years in the areas of basic, translational, or clinical research.

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions Initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Also listed under R01.

The research that we fund is vital to our mission of understanding the role of diet, nutrition, body composition and physical activity in reducing cancer risk and improving outcomes for cancer patients and survivors. Our Research Grant Program builds on and is informed by the scientific findings from our Continuous Update Project and Third Expert Report.

The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.

The BTSI is awarded to scientists at the end of their fellowship or in the beginning of their faculty appointment, who are predominantly focused on lab-based, basic/translational research. The BTSI is intended to encourage scientific inquiry in the field of basic/translational science as it relates to NETs. NANETS welcomes applications from candidates who meet the following criteria: - Candidates must have a MD, PhD, MD/PhD, DO degree or equivalent. - At the time of funding, candidates must be in the first 6 years of a faculty appointment at an accredited medical school or other institution in North America. Faculty appointments include instructors and above. - Candidates must be a NANETS member in good standing. - Previous recipients of NBTSI, NCIS or NTIG awards are not eligible to apply. Criteria for selection will include both the research proposal itself and the potential of the individual to make future scientific and/or clinical contributions to the neuroendocrine tumor field. Strong emphasis will be placed on the career development plan and the applicant's personal statements, as well as the research proposal. The research proposals section should focus on research projects with the potential to directly impact and improve the treatment of patients with neuroendocrine tumors.

Applications will be accepted for a broad range of melanoma research projects involving basic science, clinical trials, etc. 1. An adequate discussion of biostatistics is required, including but not limited to specification of numbers of cell lines, laboratory animals, or patients to be treated in the studies. 2. Plans for adjustment for multiple looks should be presented, particularly in regards to clinical endpoints and evaluation of multiple biomarkers.

LIVESTRONG Cancer Institutes' mission: To rethink the full range of cancer care, from prevention to diagnosis, treatment, survivorship and end-of-life care - all with a focus on the patient's needs, values and preferences. Projects and organizations funded must also directly support the LIVESTRONG mission and the mission of the LIVESTRONG Cancer Institutes and should not be at odds with either mission.

Each year, CLRA's Medical Advisory Committee, consisting of prominent internationally known and respected hematologists, reviews submitted research proposals from doctors nationwide. Using your contributions, we fund research grants for doctors who are conducting the most promising research into leukemia, in the hopes of isolating the causes and finding a cure for this dread disease. The objectives of this committee are to direct the funds of the Association into the most promising projects, and where funding would not duplicate other funding sources. With your help, we are getting closer every day! Because of the support of friends like you, the scientific community is making incredible strides in developing chemotherapy regimens that are extending the lives of leukemia patients. Not everyone under treatment goes into remission but our research grants are funding the examinations into why this is so, and how we can continue to combat leukemia.

The NIH Director's New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research.

The Mark Foundation Emerging Leader Awards support innovative research from the next generation of leaders in cancer research. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio.

The FY20 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research. A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations Also listed under: -Translational Research Partnership Award -Early-Career Investigator Award

 This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur.